PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY-COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN

被引：1
|
作者：
Quinzler, R. [1 ]
Ude, M. [2 ]
Franzmann, A. [1 ]
Feldt, S. [1 ]
Leuner, K. [2 ]
Mueller, W. E. [2 ]
Dippel, F. W. [3 ]
Schulz, M. [4 ]
机构：
[1] German Inst Drug Use Evaluat DAPI, GIDE, Eschborn, Hessen, Germany
[2] Goethe Univ Frankfurt, Frankfurt, Hessen, Germany
[3] Sanofi Aventis, Berlin, Germany
[4] ABDA Fed Union German Assoc Pharmacists, Berlin, Germany
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74141-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A234 / A234
页数：1
相关论文
共 50 条
  • [21] Risk of exercise induced hypoglycemia in patients with diabetes mellitus type 2 (DM2) on intensified insulin therapy (ICT): Comparison of NPH-Insulin versus glargine as basal insulin supplement
    Reuter, Thomas
    Topuz, Mendaha
    Riese, Brigitte
    Wiedenmann, Bertram
    Ploeckinger, Ursula
    [J]. DIABETES, 2007, 56 : A280 - A280
  • [22] Glargine versus NPH insulin in cystic fibrosis related diabetes
    Grover, Patricia
    Thomas, William
    Moran, Antoinette
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (02) : 134 - 136
  • [23] Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - The glargine and aspart study (GLASS) - A randomised cross-over study
    Chatterjee, S.
    Jarvis-Kay, J.
    Rengarajan, T.
    Lawrence, I. G.
    McNally, P. G.
    Davies, M. J.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 77 (02) : 215 - 222
  • [24] Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety
    Seufert, Jochen
    Wiesli, Peter
    Fritsche, Andreas
    Anderten, Helmut
    Pegelow, Katrin
    Pscherer, Stefan
    Pfohl, Martin
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 72 - 81
  • [25] Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
    Fiesselmann, Albrecht
    Wiesner, Tobias
    Fleischmann, Holger
    Bramlage, Peter
    [J]. ACTA DIABETOLOGICA, 2016, 53 (05) : 717 - 726
  • [26] Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
    Albrecht Fiesselmann
    Tobias Wiesner
    Holger Fleischmann
    Peter Bramlage
    [J]. Acta Diabetologica, 2016, 53 : 717 - 726
  • [27] Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy
    Yokoyama, Hiroki
    Tada, Junko
    Kamikawa, Futayo
    Kanno, Sakiko
    Yokota, Yuki
    Kuramitsu, Masae
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 73 (01) : 35 - 40
  • [28] A COST-MINIMIZATION ANALYSIS FOR TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETERMIR IN A BASAL SUPPORTED ORAL THERAPY IN CHINA
    Dong, H.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A60 - A61
  • [29] Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy
    Riddle, M
    Rosenstock, J
    [J]. DIABETOLOGIA, 2002, 45 : A52 - A52
  • [30] Insulin glargine: A new basal insulin
    Levien, TL
    Baker, DE
    White, JR
    Campbell, RK
    [J]. ANNALS OF PHARMACOTHERAPY, 2002, 36 (06) : 1019 - 1027
12345